cjstocksup
2 years ago
@bc9114 The $12.5m ( 5,193,187 shares) in shares distribution to G42 Healthcare were dilutive shares resulting in a increase in total outstanding shares from 90,036,637 to 95,229,824. The float will remain at 30,346,158 because G42 Healthcare will become an affiliate in the next 30 days.
βLock-Up Periodβ means the period from the date of this Agreement until December 31, 2024 (or, if earlier, the date of receipt of FDA Approval). I love this Lock-Up Period : ) which is located on page 5.
These particular shares are classified as Unregistered Securities that orginated from the LPC Agreement which had $35.9 remaining available as of March 31st, 2022 & as a result of the G42 Healthcare Partnership the remaining availability under the LPC Agreement is now at $23.4m.
Common Stock Purchase Agreement: (Unregistered Securities)
sec.gov/Archives/edgar/data...
In the next 30 days Vtv's board will increase to 6 & will add
Dr. Fahed Al Marzooqi the COO of G42 Healthcare.
cjstocksup
2 years ago
New SEC Filing: 8-K Material Agrmt - vTv Therapeutics Inc. (0001641489) May 31
Item 1.01Entry into a Material Definitive Agreement Common Stock Purchase Agreement On May 31, 2022, vTv Therapeutics Inc. (the "Company") and G42 Investments AI Holding RSC Ltd, a private limited company ("G42 Investments"), entered into a common stock purchase agreement (the "Purchase Agreement"), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share (the "Common Stock" and such shares, the "Closing Shares") at a price per share of approximately $2.41, for an aggregate purchase price of $25,000,000, which was paid (i) $12,500,000 in cash at the closing of the transaction and (ii) $12,500,000 in the (...)
marketnewswire.live/index.p...
crudeoil24
2 years ago
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
6:56 am ET June 1, 2022 (Benzinga) Print
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd ("G42 Investments"). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the "FDA") approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the United States. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the United States and the European Union.
"We have focused substantial energy and resources on TTP399 since obtaining Breakthrough Therapy designation from the FDA in April 2021 and are thrilled to welcome a partner to work with us to accelerate the development and potential approval and commercialization of this treatment. G42 Healthcare brings a unique combination of strong commitment to the development of new impactful drugs and treatments, as demonstrated by their success and their leadership on COVID-19 testing and other product and service offerings in the healthcare spectrum, and substantial resources, making them an ideal partner for this program. This investment into vTv will fund a substantial portion of our Phase 3 clinical trials for TTP399 in the United States and the collaboration with G42 will fund certain of the Phase 3 clinical trials that will be conducted in other territories. We are excited to partner with the G42 Healthcare team as we launch our Phase 3 clinical trials and work together towards approval and commercialization of this treatment for type 1 diabetes," said Rich Nelson, Interim Chief Executive Officer of vTv.
Dr. Fahed Al Marzooqi, the Chief Operating Officer of G42 Healthcare, noted that "We have a deep commitment to collaborating with international organizations to share our knowledge and expertise in the consumer and clinical health spectrum and we look forward to working together with vTv to further develop and commercialize this important treatment. As we move ahead, we will continue to join forces with the world's best to innovate and invest in science and create the next wave of medicines to future-proof the health of nations."
A more detailed description of the agreements is set forth in vTv's Current Report on Form 8-K filed with the SEC. The Stock Purchase Agreement is attached to the Current Report on Form 8-K and the Collaboration and License Agreement will be filed with vTv's Quarterly Report on Form 10-Q for the second quarter.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.